AR085837A1 - Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer - Google Patents

Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer

Info

Publication number
AR085837A1
AR085837A1 ARP120101128A ARP120101128A AR085837A1 AR 085837 A1 AR085837 A1 AR 085837A1 AR P120101128 A ARP120101128 A AR P120101128A AR P120101128 A ARP120101128 A AR P120101128A AR 085837 A1 AR085837 A1 AR 085837A1
Authority
AR
Argentina
Prior art keywords
disease
therapy
level
therapeutic level
alzheimer
Prior art date
Application number
ARP120101128A
Other languages
English (en)
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of AR085837A1 publication Critical patent/AR085837A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso del nivel de ciertas citoquinas en la sangre de un paciente como una medida objetiva con el propósito de evaluar el progreso de la enfermedad en pacientes que tienen la enfermedad de Alzheimer y con el propósito de determinar la eficacia de un régimen de tratamiento. Se proveen métodos para tratar la enfermedad de Alzheimer y controlar la eficacia terapéutica.Reivindicación 1: Un método para evaluar la eficacia de una terapia pretendida para tratar la enfermedad de Alzheimer, caracterizado porque comprende los pasos de: (a) determinar el nivel promedio de una citoquina en una muestra de sangre tomada de sujetos que sufren de la enfermedad de Alzheimer pero no reciben la terapia, para obtener de ese modo un nivel no terapéutico de la citoquina; (b) determinar el nivel promedio de la citoquina en una muestra de sangre tomada de sujetos que sufren de la enfermedad de Alzheimer y que reciben la terapia, para obtener de ese modo un nivel terapéutico de la citoquina; y (c) comparar el nivel terapéutico con el nivel no terapéutico, para determinar de ese modo la eficacia de la terapia, donde la terapia se considera efectiva cuando el nivel terapéutico es más alto que el nivel no terapéutico, y la terapia se considera inefectiva cuando el nivel terapéutico es igual o más bajo que el nivel no terapéutico, donde tanto los sujetos en (a) como los sujetos en (b) incluyen al menos 5 individuos.
ARP120101128A 2011-04-01 2012-03-30 Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer AR085837A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161470819P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
AR085837A1 true AR085837A1 (es) 2013-10-30

Family

ID=46208748

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101128A AR085837A1 (es) 2011-04-01 2012-03-30 Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer

Country Status (12)

Country Link
US (1) US20120251524A1 (es)
EP (1) EP2694978A1 (es)
JP (1) JP2014513284A (es)
KR (1) KR20130143659A (es)
CN (1) CN103547924A (es)
AR (1) AR085837A1 (es)
AU (1) AU2012236137A1 (es)
BR (1) BR112013025197A2 (es)
CA (1) CA2831863A1 (es)
MX (1) MX2013011325A (es)
TW (1) TW201250247A (es)
WO (1) WO2012135752A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
WO2014182631A1 (en) * 2013-05-06 2014-11-13 Baxter International Inc. Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
CN105353135A (zh) * 2015-11-23 2016-02-24 中国人民解放军第三军医大学第一附属医院 阿尔茨海默病标志物的用途
EP4210719A1 (en) * 2020-09-08 2023-07-19 Longeveron Inc. Treatment of alzheimer's disease with allogeneic mesenchymal stem cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1692520A2 (en) * 2003-11-19 2006-08-23 Satoris, Inc. Method for diagnosis, stratification and monitoring of alzheimer's disease
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
CN102178953A (zh) * 2005-02-14 2011-09-14 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
WO2007059135A2 (en) * 2005-11-10 2007-05-24 Satoris, Inc. Methods of treating alzheimer's disease
WO2008008819A2 (en) * 2006-07-11 2008-01-17 University Of Florida Research Foundation, Inc. Diagnosis and treatment of neurological inflammation
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
ES2477271T3 (es) * 2007-08-13 2014-07-16 Baxter International Inc. Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson
US20100124756A1 (en) * 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US20110250206A1 (en) * 2010-02-11 2011-10-13 Axtell Robert C Markers for determination of patient responsiveness
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs

Also Published As

Publication number Publication date
MX2013011325A (es) 2014-07-09
JP2014513284A (ja) 2014-05-29
CA2831863A1 (en) 2012-10-04
BR112013025197A2 (pt) 2019-09-24
CN103547924A (zh) 2014-01-29
US20120251524A1 (en) 2012-10-04
TW201250247A (en) 2012-12-16
EP2694978A1 (en) 2014-02-12
WO2012135752A1 (en) 2012-10-04
KR20130143659A (ko) 2013-12-31
AU2012236137A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
PH12017501253A1 (en) Method and apparatus for the measurement of autonomic function for the diagnosis and validation of patient treatments and outcomes
BR112013013460A8 (pt) métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total
MX363322B (es) Metodos, aparatos y sistemas para el diagnostico y tratamiento de trastornos del estado de animo.
EP2572637A4 (en) DEVICE FOR THE EXAMINATION OF THE NERVOUS FUNCTION
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
BR112015012731A2 (pt) uso de eribulina no tratamento de câncer de mama
MX2013000675A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
MX2009012174A (es) Metodos para detectar daño cardiaco.
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
DK2903616T3 (da) Anvendelse af masitinib i kombination med gemcitabin til behandling af en undergruppe af patienter, der lider af pankreascancer
EP3879269A3 (en) Methods of measuring signaling pathway activity for selection of therapeutic agents
AR085837A1 (es) Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer
EA201700123A1 (ru) Способ прогнозирования варианта лекарственного препарата для лечения депрессии
WO2013071012A3 (en) Personalized strategic cancer treatment
CL2020002047A1 (es) Métodos terapéuticos y diagnósticos para enfermedades inflamatorias mediadas por mastocitos.
BR112023018220A2 (pt) Método para diagnóstico e tratamento de lesão tecidual profunda usando medições de umidade subepidérmica
CO6592030A2 (es) Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa
CL2016000641A1 (es) Un controlador para un dispositivo para administrar un medio de contraste que comprende un agente de contraste radiológico en un paciente usando un inyector, y método para determinar el volumen óptimo de un medio de contraste que comprende un agente de contraste radiológico que ha de administrarse en un paciente, antes de la administración.
GB201121914D0 (en) Method for patient selection
WO2015017506A3 (en) Nanoparticle diagnostic and methods for treating disease
RU2011122721A (ru) Способ оптимизации лечения хронического миелолейкоза ингибиторами тирозинказы abl
EA201001297A1 (ru) Способ диагностики меланомы человека на основании определения уровня экспрессии гена phf10, диагностический набор
CR10486A (es) Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico

Legal Events

Date Code Title Description
FB Suspension of granting procedure